

Referral Possibilities for Patients with Indeterminate FNA Cytology and Additional ThyroSPEC™ Testing

low malignancy risk molecular findings

- **Non-BRAF-Non-RAS-like Mutations**¹: Bethesda III (AUS/FLUS) – post-test >15% risk of malignancy; Bethesda IV (FN/SFN) – post-test >38% risk of malignancy
- **RAS-like Mutations**^{1,3}: Bethesda III (AUS/FLUS) – post-test 73% risk of malignancy⁴; Bethesda IV (FN/SFN) – post-test 44% risk of malignancy⁴

**Central Access and Triage
Endocrinology and Metabolism - Calgary**
Richmond Road Diagnostic and Treatment Center
1820 Richmond Road SW
Calgary, AB T2T 5C7
Phone: 403-955-8633
Fax: 403-955-8634
Endo.CAT@albertahealthservices.ca

high malignancy risk molecular findings

- **BRAF-like Mutations**^{1,3}: indicate a malignant tumour (>90% risk of malignancy)
- **High-Risk Mutations**⁵: indicate a malignant tumour with poor prognosis (100% risk of malignancy)
- **RET Mutations**

Endocrine Surgeons Offices - Calgary
Dr. Janice Pasioka, Phone: 403-944-2491, Fax: 403-283-4130
Dr. Adrian Harvey, Phone: 403-944-0966, Fax: 403-944-6008
ENT Thyroid Surgeons Offices - Calgary
Dr. Shamir Chandarana, Phone: 403-944-3954, Fax: 403-210-9828
Dr. Robert Douglas Hart, Phone: 403-944-3162, Fax: 403-991-7070
Dr. Derrick Randall, Phone: 403-282-0054, Fax: 403-282-0059
Dr. Joe Warshawski, Phone: 403-571-5215, Fax: 403-571-5204
Red Deer
Dr. Arone Pabbies, Phone: 403-342-0494, Fax: 403-343-0304

¹ Yoo SK et al., 2016 *PLOS Genetics*, 12(8):e1006239

² Ye L et al., 2017, *Nature Communications*, 8:15533. doi: 10.1038/ncomms15533.

³ The Cancer Genome Atlas Research Network, 2014, *Cell*, 159(3):676-90

⁴ Stewardson P et al., American Thyroid Association Annual Meeting in Chicago, IL, November 2019

⁵ Ricarte-Filho JC et al., 2009, *Cancer Research*, 69(11):4885-93